Krystal Biotech to Present at Upcoming Scientific Conferences

PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific conferences being held in May and June.

Presentation details are outlined below.

American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Poster Presentation

American Thoracic Society (ATS) International Conference 2026

Oral Presentation

2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Poster Presentation

Additional presentation details will be available to conference attendees. Following completion of each conference, presentation slides or posters, as applicable, will also be available to view online on the Investor section of the Company’s website.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK ®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X.

CONTACT

Investors and Media:

Stéphane Paquette, PhD

Krystal Biotech

spaquette@krystalbio.com